Recognizing Hypercortisolism in Patients with Type 2 Diabetes in Primary Care

Patients who keep missing treatment goals despite good therapy may be facing an unrecognized hormonal driver that primary care is now positioned to catch early.

The panel of experts examines how the CATALYST trial is changing the way primary care clinicians recognize hypercortisolism in patients with difficult-to-control type 2 diabetes.

Expert faculty demonstrate how practical hypercortisolism screening can be in primary care when clinicians know which test to use and how to use it.

Expert faculty discuss how treatment outcomes and emerging evidence strengthen the case for earlier recognition of hypercortisolism in primary care.

Expert faculty examine how resistant hypertension may signal underlying hypercortisolism and discuss when clinicians should think beyond routine blood pressure management.

Recognizing hypercortisolism is only the first step. Expert faculty discuss how thoughtful evaluation, strong clinical advocacy, and coordinated referral can help patients receive timely diagnosis and appropriate care.

Expert faculty demonstrate how thoughtful screening and careful interpretation can help primary care clinicians recognize hypercortisolism earlier and with greater confidence.